Key result
Asymmetric dimethylarginine (ADMA) functions as an endogenous inhibitor of nitric oxide synthase, regulating nitric oxide generation in cardiovascular disease states.
Key points are not available for this paper at this time.
Design
Review
This review highlights the role of asymmetric dimethylarginine (ADMA) as an endogenous inhibitor of nitric oxide synthase in cardiovascular physiology and disease.
An increasing number of reports indicate that endogenously produced inhibitors of nitric oxide synthase, particularly asymmetric dimethylarginine (ADMA), regulate nitric oxide generation in disease states. This article describes the biology of ADMA and the implications for cardiovascular physiology and pathophysiology.
No takes yet. Share an insight, caveat, or question.
Vallance et al. (2004) studied this question. Asymmetric dimethylarginine (ADMA) functions as an endogenous inhibitor of nitric oxide synthase, regulating nitric oxide generation in cardiovascular disease states.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: